PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer
Unprecedented: This preliminary study showed complete responses in 100% of patients with locally advanced rectal cancer with mismatch repair-deficient (dMMR) tumors - a hallmark of Lynch Syndrome.
This ongoing trial at Memorial Sloan Kettering will ultimately enroll more patients.